Metraipolis › archive › dc_f37efe19bd85

BP1.4979 — Wikipedia (en)

Source: Wikipedia (en)
Original: https://en.wikipedia.org/wiki/BP1.4979
License (as archived): CC-BY-SA-4.0
Archived: 2026-11-10T17:46:48.415Z
SHA-256 of the archived text: 90644408afca617989596b9286f650eb94957d59ea4900488e30d63d640057fd
Stable URL of this page: https://metraipolis.com/documento/dc_f37efe19bd85

How to cite

BP1.4979 — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/BP1.4979 (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_f37efe19bd85 (Metraipolis archive dc_f37efe19bd85, sha256 90644408afca617989596b9286f650eb94957d59ea4900488e30d63d640057fd)

BibTeX

@misc{dcf37efe19bd85,
  title = {BP1.4979 — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/BP1.4979},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_f37efe19bd85; sha256 90644408afca617989596b9286f650eb94957d59ea4900488e30d63d640057fd},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/BP1.4979. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

BP1.4979 is a selective dopamine D3 receptor agonist which is under development for the treatment of binge-eating disorder, obsessive–compulsive disorder (OCD), restless legs syndrome (RLS), and smoking withdrawal. It is taken orally. The drug acts as a highly potent weak partial agonist of the dopamine D3 receptor (Ki = ~1 nM; EC50Tooltip half-maximal effective concentration = 0.7 nM; EmaxTooltip maximal efficacy = 32%). It has around 200-fold higher affinity for the dopamine D3 receptor than for the dopamine D2 receptor (Ki = 192 nM), where it is an antagonist. BP1.4979 showed 66% dopamine D3 receptor occupancy and 8% dopamine D2 receptor occupancy with positron emission tomography (PET) imaging in a clinical study. The time to peak levels of BP1.4979 is 1 hour and its elimination half-life is about 8 hours. The drug is under development by Bioprojet. As of January 2026, it is in phase 2 clinical trials for all indications.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «BP1.4979» — https://en.wikipedia.org/wiki/BP1.4979
Wikidata Q138019904: «pharmaceutical compound» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q138019904
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/BP1.4979?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1372016782, consultata il 2026-11-10T17:43:54.454Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: fdac15f97b5298af1a390908ae0cf6aaed42822b9ecc3e5fb78973ce06b0aef2